UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of May 2021
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Publication of Base Prospectus
The following base prospectus dated 10 May 2021 has been approved
by the Financial Conduct Authority and is available for
viewing:
GlaxoSmithKline plc, GlaxoSmithKline Capital plc, GSK Capital B.V.
and GSK Capital K.K. £20,000,000,000 Euro Medium Term Note
Programme
Copies of the base prospectus and the documents incorporated by
reference within it have been submitted to the UK Listing
Authority's NSM submission portal via the Electronic
Submission System (ESS). The base prospectus will shortly be
available for inspection at and can be downloaded
from:
https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
For further information, please contact:
GlaxoSmithKline plc
980 Great West Road
Brentford
Middlesex
TW8 9GS
United Kingdom
Enquiries:
UK
Media enquiries:
|
Mary
Hinks-Edwards
David
Mawdsley
Simon
Steel
|
+44 (0)
20 8047 5502
+44 (0)
20 8047 5564
+44 (0)
20 8047 3763
|
European
Analyst/Investor enquiries:
|
James
Dodwell
Danielle
Smith
|
+44 (0)
20 8047 2406
+44 (0)
20 8047 0932
|
BASIS ON WHICH YOU MAY ACCESS THE BASE PROSPECTUS
Please note that the information contained in the base prospectus
may be addressed to and/or targeted at persons who are
residents of particular countries (specified in the base
prospectus) only and is not intended for use and should not be
relied upon by any person outside these countries and/or
to whom the offer contained in the base prospectus is not
addressed. Prior to relying on the information contained in
the base prospectus you must ascertain from the base prospectus
whether or not you are part of the intended addressees of
the information contained therein.
Your right to access this service is conditional upon complying
with the above requirements.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: May
11, 2021
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|